Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Blood Advances|October 8, 2020
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyJoanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, et al.
Blood|April 4, 2020
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclaxVictor S Lin, Thomas E Lew, Sasanka M Handunnetti, et al.
British Journal of Haematology|March 3, 2025
Heterozygous germline TET2 loss-of-function variants associated with an ALPS-like phenotypeSean Harrop, Joshua Casan, Hannah Rose, et al.
The Lancet. Haematology|June 1, 2023
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibilityGeorgia S Mills, Verity Chadwick, Catherine Tang, et al.
Expert Review of Hematology|August 1, 2025
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapyValeriya Kuznetsova, Hannah Rosenfeld, Carmela Sales, et al.
Leukemia & Lymphoma|October 11, 2021
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trialTara Cochrane, Alicia Enrico, David Gomez-Almaguer, et al.
Blood Advances|December 3, 2021
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitorsElla R Thompson, Tamia Nguyen, Yamuna Kankanige, et al.
BMJ Neurology Open|September 19, 2024
Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective studyValeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, et al.
BMJ Neurology Open|March 25, 2026
Neurological implications of chimeric antigen receptor-T cell therapyDaniel G Raffoul, Izanne Roos, Matthias Mulazzani, et al.
Blood Advances|September 3, 2021
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibitionThomas E Lew, Victor S Lin, Edward R Cliff, et al.
Pageof 10